751 related articles for article (PubMed ID: 10954253)
1. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
3. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
4. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
6. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
7. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
8. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
9. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Vaziri SA; Krumroy LM; Rostai M; Casey G
Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
11. Psychological impact of receiving a BRCA1/BRCA2 test result.
Lodder L; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Duivenvoorden HJ; Tibben A; Wagner A; van der Meer CA; van den Ouweland AM; Niermeijer MF
Am J Med Genet; 2001 Jan; 98(1):15-24. PubMed ID: 11426450
[TBL] [Abstract][Full Text] [Related]
12. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
[TBL] [Abstract][Full Text] [Related]
13. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
14. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
[TBL] [Abstract][Full Text] [Related]
15. [Recommendations for the management of women with an increased genetic risk of gynaecological cancer].
Verheijen RH; Boonstra H; Menko FH; de Graaff J; Vasen HF; Kenter GG
Ned Tijdschr Geneeskd; 2002 Dec; 146(50):2414-8. PubMed ID: 12518519
[TBL] [Abstract][Full Text] [Related]
16. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition].
Ruiz-Flores P; Calderón-Garcidueñas AL; Barrera-Saldaña HA
Rev Invest Clin; 2001; 53(1):46-64. PubMed ID: 11332051
[TBL] [Abstract][Full Text] [Related]
17. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
18. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
Vahteristo P; Eerola H; Tamminen A; Blomqvist C; Nevanlinna H
Br J Cancer; 2001 Mar; 84(5):704-8. PubMed ID: 11237395
[TBL] [Abstract][Full Text] [Related]
19. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
20. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
